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Summary
Background: Phosphorylation of the transcriptional coacti-
vator YAP1 is a key event in defining Hippo signaling outputs.
Previous studies demonstrated that phosphorylation of YAP1
at serine 127 (S127) sequesters YAP1 in the cytoplasm and
consequently inhibits YAP1 transcriptional activity. Mamma-
lian tissue-culture experiments suggest that downstream
of MST1/2 signaling, LATS1/2 function as YAP1-S127 kinases.
However, studies of Mst1/2 knockout mouse models re-
vealed that the identity of the physiological YAP1-S127 ki-
nase(s) in certain tissues, such as the intestine, remains
unknown.
Results:Weshow thatmammalian NDR1/2 kinases phosphor-
ylate YAP1 on S127 and thereby negatively regulate YAP1
activity in tissue-cultured cells. By studying NDR1/2-deficient
mice, we demonstrate the in vivo relevance of NDR1/2-medi-
ated regulation of YAP1. Specifically, upon loss of NDR1/2 in
the intestinal epithelium, endogenous S127 phosphorylation
is decreased whereas total YAP1 levels are increased. Signifi-
cantly, ablation of NDR1/2 from the intestinal epithelium
rendersmice exquisitely sensitive to chemically induced colon
carcinogenesis. Analysis of human colon cancer samples
further revealed that NDR2 and YAP1 protein expression are
inversely correlated in the majority of samples with high
YAP1 expression. Collectively, we report NDR1/2 as physio-
logical YAP1-S127 kinases that might function as tumor sup-
pressors upstream of YAP1 in human colorectal cancer.
Conclusions: We establish mammalian NDR1/2 as bona fide
kinases that target YAP1 on S127 in vitro and in vivo. Our find-
ings therefore have important implications for a broad range of
research efforts aimed at decoding and eventually manipu-
lating YAP1 biology in cancer settings, regenerative medicine,
and possibly also noncancer human diseases.Introduction
The transcriptional coactivator YAP1 and its fly counterpart
Yorkie drive tissue and organ growth in flies and mammals
[1]. Originally delineated in flies, the Hippo kinase phosphory-
lates the Lats/Warts kinase, which in turn restricts Yorkie*Correspondence: a.hergovich@ucl.ac.uk (A.H.), debora.schmitz@fmi.ch
(D.S.-R.)activity by phosphorylating serine 168 (S168) [2]. The core of
the mammalian Hippo pathway is composed of MST1/2 and
LATS1/2 kinases, the mammalian Hippo and Lats/Warts
homologs. MST1/2 phosphorylate LATS1/2, which in turn
phosphorylate YAP1 on serine 127 (S127), the mammalian
equivalent of Yorkie S168 [3], resulting in cytoplasmic reten-
tion and decreased transcription of YAP1 target genes [4].
Overexpression studies of YAP1 in transgenic mice revealed
YAP1 as a player in cellular transformation in vivo [5, 6]. Subse-
quent mouse models demonstrated that MST1/2 kinases
are required to suppress the oncogenic potential of YAP1 in
the liver and the intestinal epithelium [7–10], yet none of these
models provided strong evidence for LATS1/2 as direct YAP1-
S127 kinases. One study suggested that in the liver, MST1/2
activate a kinase distinct from LATS1/2 to phosphorylate
YAP1 on S127 [9]. Another study did not address how deregu-
lation of MST1/2 impacts on S127 phosphorylation in the
liver [8]. In the intestinal epithelium, ablation of MST1/2 kinase
activity results in YAP1-dependent crypt hyperplasia [10, 11].
However, the YAP1-S127 kinase functioning downstream
of MST1/2 was not addressed in the intestinal epithelium
[10, 11].
Mammalian NDR kinases are the closest homologs of
LATS1/2 [12]. The mammalian genome encodes two highly
similar isoforms, NDR1 and NDR2, which are located at
distinct genomic loci [13]. Functionally, NDR kinases have
been reported to regulate centrosome duplication [14, 15],
apoptosis [16, 17], proliferation [18], and chromosome align-
ment [19, 20] in tissue-cultured cells. We previously published
that loss of Ndr1 predisposes mice to T cell lymphoma devel-
opment [16], suggesting a tumor-suppressive function of
mammalian NDR kinases. The same study showed that
NDR2 protein, but not mRNA, is upregulated upon genetic
Ndr1 deletion, suggesting that compensatory effects between
the two mammalian NDR isoforms prevent the discovery of
additional physiological functions of NDR kinases.
In summary, in the intestinal epithelium, direct physiological
regulators of YAP1 by phosphorylation are currently unknown.
The present study shows that mammalian NDR kinases phos-
phorylate YAP1 on S127 in vitro in tissue-cultured cells and
in vivo in the intestinal epithelium. Phosphorylation of YAP1
at S127 by NDR mediates sequestration of YAP1 in the cyto-
plasm, restricts the transcriptional coactivator function of
YAP1, and suppresses proliferation of human colon cancer
cells.
Results
Mammalian NDR Kinases Restrain Proliferation and
Hyperplastic Growth in the Intestinal Epithelium
NDR1 protects against T cell lymphoma development and
is highly expressed in organs of the immune system.
Conversely, NDR2 is most abundant in the gastrointestinal
tract [13, 16]. Therefore, we hypothesized that NDR2 might
function as a tumor suppressor in the colonic epithelium. To
test this hypothesis and avoid compensation by NDR1, we ab-
lated NDR2 specifically in the intestinal epithelium of Ndr1 null
mice (Figure S1A available online) [16, 21]. Specific ablation of
NDR2 in the intestinal epithelium, denotedN2 cKO (conditional
Figure 1. Mammalian NDR Kinases Restrain Pro-
liferation and Hyperplastic Growth in the Intesti-
nal Epithelium
(A and B) Hyperplastic patches in the intestinal
epithelium of N1/2 cDKO (Ndr12/2Ndr2f/f Vil-
Cre+) mice (A: small intestine; B: colon) visualized
by H&E staining. Larger magnification of the hy-
perplastic areas and control regions are shown
below. Scale bars represent 400 mm (upper
panels) and 100 mm (lower panels).
(C and D) Ki-67 IHC staining (brown) inN1/2 cDKO
and control mice (top) and corresponding quanti-
fication (bottom) (C: small intestine; D: colon).
Numbers represent the average of a total of 200
crypts counted in five mice per genotype.
Student’s t test: *p1 = 3 3 1027, *p2 = 4 3 1028,
*p3 = 9 3 1023, *p4 = 3 3 1023. Scale bars repre-
sent 100 mm.
See also Figure S1.
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with an NDR2-specific antibody (Figure S1B). Ndr1 null mice
lacking NDR2 in the intestinal epithelium, denoted N1/2
cDKO (conditional double knockout), were born in the ex-
pected Mendelian ratios, developed no obvious morpholog-
ical abnormalities, and did not display spontaneous tumor
formation in the colon (monitored for up to 24 months; data
not shown). However, the intestinal epithelium of N1/2 cDKO
adult mice (aged 16–20 weeks) displayed hyperplastic areas,
which were absent in Ndr1 and Ndr2 single KO and wild-type
controls (Figures 1A and 1B; data not shown). Subsequent his-
tological analyses revealed that the secretory lineage and
absorptive enterocytes in N1/2 cDKOmice were indistinguish-
able from control animals (Figure S1C). Taken together, these
findings suggest that mammalian NDR prevents hyperplastic
growth in the intestinal epithelium but is dispensable for differ-
entiation of the secretory lineage and absorptive enterocytes.
Further histological analyses of N1/2 cDKO intestines re-
vealed the presence of aberrant crypts, characterized by
enlarged nuclei, a thickened epithelial cell layer, and loss of
apical-basal polarity (Figure S1D). These abnormal crypts
resembled so-called b-catenin-accumulated crypts (BCACs),
which have been proposed as biomarkers for colon carcino-
genesis in rodents and humans [22]. Indeed, we detected
increased b-catenin levels in aberrant crypts in N2 cKO and
N1/2 cDKO but not in wild-type, wild-type-Vil-Cre, or N1 KO
mice (Figure S1E), suggesting that NDR2 ablation can result
in BCAC formation.
To characterize the hyperplastic phenotype of N1/2 cDKO
intestines further, we determined the proliferation index of
N1/2 null and control epithelia (Figures 1C and 1D; Figure S1F).
The entire proliferative zone of N1/2 null colonic epithelia in
both normal and hyperplastic areas was extended 2-fold
compared to wild-type and Ndr1 single KO mice. N2 cKO
colonic epithelia displayed an intermediate increase in prolifer-
ation, indicating that NDR1 compensates only partially forNDR2 loss in this compartment. To
further analyze the proliferative behavior
of NDR-deficient intestinal epithelial
cells (IECs), we performed colony forma-
tion assays as described [23] revealing
that primary IECs isolated from N1/2
cDKO mice formed similar numbers of
colonies as controls (data not shown).However, N1/2 null colonies grew significantly larger than
wild-type colonies (Figure S1F). In summary, our data indicate
that mammalian NDR kinases restrict proliferation of intestinal
epithelial cells in vivo.
NDRProtectsMice against Azoxymethane/Dextran Sodium
Sulfate-Induced Colon Carcinogenesis
Although N1/2 cDKO mice developed intestinal hyperplasia
and BCACs (Figure 1; Figures S1C and S1D), we did not
observe progression to adenocarcinoma in the genetic back-
ground analyzed (mixed C57B/L6-Ola129). Spontaneous
colon cancer development in rodents is rare [24]. Therefore,
we assessed whether NDR protects mice against chemically
induced colon carcinogenesis [25]. Ndr KO and control mice
were treated with the colonotropic mutagen azoxymethane
(AOM) and the inflammatory agent dextran sodium sulfate
(DSS) as depicted in Figure 2A. Regardless of NDR status, all
but one control mouse developed colonic nodules, indicating
that the treatment reproducibly induced colon carcinogenesis.
A representative pair of AOM/DSS-treated N1/2 cDKO versus
control colon is shown in Figure 2B. Based on histopatholog-
ical analysis, all nodules analyzed were diagnosed as adeno-
carcinoma (Figure 2C; Figure S2). However, whereas control
mice (WT Vil-Cre) developed 2 or 3 nodules throughout their
colon, N1/2 cDKO mice developed 16 nodules on average
(Figure 2D; Table S1). Although nodule lumping precluded
rigorous quantification of nodule size in N1/2 cDKO epithelia,
isolated nodules appeared to be of similar size in KO and con-
trol animals at dissection (data not shown). Ablation of Ndr2
alone increased the average nodule number per mouse to
six, whereas Ndr1 single KO had no effect on nodule numbers
compared to controls (Figure 2D). Intriguingly, these observa-
tions fully parallel our in vivo proliferation measurements (Fig-
ures 1C and 1D), namely that loss of NDR2 alone, but not loss
of NDR1, increases proliferation in the colonic epithelium,
which is further increased in N1/2 cDKO mice (Figure 1D).
Figure 2. NDR Kinases Protect against AOM/
DSS-Induced Colon Carcinogenesis
(A) AOM/DSS treatment protocol. Arrows indicate
time points of tissue analysis in wild-type mice
(see Figure 3). D, day.
(B) Representative pair of N1/2 cDKO and control
colons post-AOM/DSS treatment after dissection
at day 64.
(C) H&E-stained sections of colon nodules in
AOM/DSS-treated N1/2 cDKO and control mice
after dissection at day 64. Scale bars represent
500 mm (upper panels) and 100 mm (lower panels).
(D) Quantification of colon nodule numbers in N1/
2 cDKO and control mice post-AOM/DSS treat-
ment after dissection at day 64. Lines indicate
the average tumor number in a given group.
Student’s t test: p1 = 9 3 1026, p2 = 0.02, p3 =
8 3 1023.
See also Figure S2 and Table S1.
298Taken together, our data indicate that mammalian NDR ki-
nases suppress tumor initiation in the intestinal epithelium.
NDR2 Protein Is Progressively Lost during AOM/DSS-
Induced Colon Carcinogenesis
Having shown that NDR partially protects against AOM/DSS-
induced carcinogenesis in Ndr KO mice, we next took the
reverse approach and applied the AOM/DSS model to wild-
type mice to assess whether NDR2 expression was lost during
colon carcinogenesis. We subjected wild-type mice to the
AOM/DSS protocol described in Figure 2A. Changes in the
colonic epithelium were monitored at the time points indi-
cated: prior to the AOM injection (day 0), day 7, day 21 (upon
completion of DSS administration), day 42, and at termination
(day 64). AOM treatment induces changes in b-catenin locali-
zation [26, 27], a hallmark of human colorectal cancer [28].
Therefore, we assessed b-catenin expression together with
hematoxylin and eosin (H&E) and Ki-67 staining to evaluate
molecular, morphological, and proliferative changes. In paral-
lel, we monitored NDR2 protein expression using our isoform-
specific antibody (Figure S1B). As expected, naive control
mice displayed an intact colonic epithelium and cytoplasmic
b-catenin localization and proliferating cells were confined to
the crypt base (Figure 3A, I, III, and IV). NDR2 expression
was detected throughout the entire epithelium (Figure 3A, II).
One week after AOM injection (Figure 3B), tissue architecture,
b-catenin localization, and NDR2 levels remained unchanged
whereas the Ki-67-positive compartment appeared slightly
extended upward (Figure 3B, IV). After DSS treatment (day
21), the colonic epithelium was destroyed and crypt regenera-
tion was apparent (Figure 3C). Some crypts showed aberrant
morphology (Figure 3C, I). b-catenin signals were increased
and occasionally nuclear (Figure 3C, III). Aberrant crypts dis-
played strong Ki-67 expression, indicating elevated prolifera-
tion rates (Figure 3C, III and IV). NDR2 levels appeared gener-
ally decreased, in line with our hypothesis that NDR restricts
proliferation in the intestinal epithelium (Figure 3C, II). On day
42, aberrant crypts had formed in the regenerated colonicepithelium (Figure 3D, I). We did not
detect adenoma or adenocarcinoma at
this time point. b-catenin and Ki-67 sig-
nals were comparable to the previous
time point (day 21) (Figure 3D, III and
IV). However, NDR2 levels in aberrantcrypts were diminished compared to adjacent normal crypts
(Figure 3D, II). Nine weeks after AOM injection (day 64), adeno-
carcinomas had formed and b-catenin signals were strongly
increased, displaying nuclear localization (Figure 3E, I and
III). The majority of cells within the nodules were Ki-67 positive
(Figure 3E, IV). Whereas stroma cells retained residual NDR2
levels, NDR2 protein was absent in the majority of adenocarci-
noma nodules (Figure 3E, II). Importantly, NDR2 protein levels
in adjacent normal crypts were comparable to those detected
prior to AOM treatment (compare Figure 3A, II and Figure 3E,
II). In summary, NDR2 protein is progressively lost during
AOM-induced colon carcinogenesis and absent in adenocar-
cinoma, supporting our hypothesis that NDR2 functions as a
tumor suppressor protein in the colon.
Levels of the YAP1 Oncoprotein Are Increased upon NDR
Ablation
The Hippo-YAP1 pathway regulates organ growth [29, 30].
Current evidence suggests that the Hippo core kinase
cassette—MST1/2 and LATS1/2 in mammals—inactivates
the transcriptional coactivator YAP1 by LATS1/2-mediated
phosphorylation. Upon phosphorylation at serine 127 by
LATS kinases [4, 6], YAP1 can be retained in the cytoplasm.
Phosphorylation of serine 381 (S381) by LATS can trigger
YAP1 degradation [31]. In the absence of Hippo pathway activ-
ity, YAP1 can enter the nucleus and drive proproliferative gene
expression. Although YAP1 is dispensable for normal intesti-
nal development and homeostasis [11], its oncogenic potential
is unleashed in the absence of Hippo pathway activity [10, 11].
Importantly, whether LATS1/2 can directly regulate YAP1 in
the intestinal epithelium remains to be addressed [10]. NDR
kinases are the closest homologs of LATS kinases [12]. Hao
et al. [32] reported that human NDR can phosphorylate YAP1
in vitro. However, neither the phosphorylation site(s) nor
the biological significance of this phosphorylation event
was examined. Therefore, we hypothesized that NDR kinases
might regulate YAP1 in the intestinal epithelium, which could
explain why N1/2 cDKO animals are more susceptible to
Figure 3. NDR2 Protein Is Progressively Lost during Colon Carcinogenesis
Tissue architecture (H&E) and NDR2, b-catenin, and Ki-67 IHC staining of the colonic epithelium of wild-type C57BL6 mice after AOM/DSS. Serial sections
were taken for the different stainings at each time point. Arrows indicate aberrant crypts. Scale bars represent 100 mm. Three mice were analyzed for each
time point, as follows.
(A) Prior to AOM injection.
(B) D7: 1 week after AOM intraperitoneal injection.
(C) D21: 1 week after completion of 2% DSS treatment.
(D) D42: 3 weeks after completion of 2% DSS treatment.
(E) D64: 6 weeks after completion of 2% DSS treatment and the end of the time course.
299chemically induced tumorigenesis. To examine this hypothe-
sis, we asked whether loss of NDR deregulates YAP1 activity
by altering YAP1 phosphorylation in the intestinal epithelium.
Murine S112 is the equivalent of human S127 [3]. Significantly,
phospho-S112 levels were decreasedwhereas total YAP1 pro-
tein levels were increased in lysates of the intestinal epithelium
derived fromN2 cKOandN1/2 cDKOmice (Figures 4A and 4B).
In contrast, phosphorylation of YAP1 at S382, the murine
equivalent of human S381, was unaffected (Figure 4A). Impor-
tantly, LATS1 total protein levels and LATS activity as deter-
mined by phosphorylation status were unchanged. Total
MST1 and phospho-MST1/2 (Thr183/180) levels, indicative of
MST1/2 activity, also remained unchanged (Figure 4A). These
findings demonstrate that the observed decrease of YAP1
phosphorylation was caused by the absence of NDR kinases
and not altered MST-LATS signaling. Immunohistochemistry
(IHC) staining of tissue sections confirmed the upregulation
of YAP1 protein in the intestinal epithelium of N1/2 cDKO
and N2 cKO mice and revealed that YAP1 is mainly nuclear
both in KO and control animals (Figure 4C; Figures S3A–S3D).
To define whether decreased YAP1 phosphorylation and
elevated YAP1 protein levels upon loss of NDR translated
into increased YAP1 activity in vivo, we employed twocomplementary approaches. YAP1 overexpression in the in-
testine correlates with downregulation of the tumor suppres-
sor PTEN [33], exerting its tumor-suppressive functions in
part by decreasing Cyclin D1 levels [34]. In agreement with
increased YAP1 activity upon NDR loss, we found decreased
PTEN and increased Cyclin D1 protein levels in N1/2 null co-
lons (Figures 4A and 4D; Figures S3E–S3H). As a second
approach, we assessed the expression of YAP1 target gene
expression in the intestinal epithelium of N1/2 cDKO mice by
in situ hybridization (ISH). CTGF, an established transcriptional
target of YAP1/TEAD [35], was only detectable in the intestinal
stroma (data not shown), a tissue where Ndr2 is not deleted by
the Villin-Cre transgene in our KO mice. Thus, we examined
BDNF, another YAP1 target gene [35], by ISH, revealing that
Bdnf transcripts were more than 2-fold upregulated in N1/2
cDKO mice compared to controls (Figure 4E; Figures S3I and
S3J), indicating that NDR restrains YAP1 target gene expres-
sion in vivo. Taken together, our data suggest that elevated
YAP1 levels upon loss of NDR translate into increased YAP1
activity in vivo.
Next, to test the relevance of YAP1 regulation by NDR in the
intestinal epithelium, we asked whether the observed hyper-
sensitivity to chemical carcinogenesis of N1/2 cDKO mice
Figure 4. Loss of NDR Causes YAP1 Upregulation in the Intestinal Epithelium
(A) Western blot analysis of total colon lysates using the indicated antibodies.
(B) Quantification of total YAP1 levels from (A) normalized to tubulin in different genotypes relative to WT. Each bar represents the western blot (WB) signal
intensity of three different mice. Student’s t test: p1 = 0.02, p2 = 0.03.
(C) YAP1 IHC staining (brown) in the colon of N1/2 cDKO and control mice (WT Vil-Cre). Bottom: YAP1 staining without counterstain. Scale bars represent
30 mm. See Figure S3D for quantification.
(D) PTEN IHC staining (brown) in the colon of N1/2 cDKO and control mice. Scale bars represent 100 mm. See Figure S3H for quantification.
(E) Bdnf in situ hybridization (brown) in the colon of N1/2 cDKO and control mice and quantification. Student’s t test: p = 3 3 1024. Scale bars represent
50 mm. See also Figures S3I and S3J.
(F) Quantification of colon nodule numbers inN1/2 cDKOandN1/2 cDKOmicewith heterozygous deletion ofYap1 post-AOM/DSS treatment after dissection
at day 64. Lines indicate the average tumor number in a given group. Student’s t test: p = 6.7 3 1026.
See also Figures 2D and S3.
300was functionally linked to YAP1 levels. To address this ques-
tion, we concomitantly ablated YAP1 in N1/2 cDKO mice and
subjected them to AOM-mediated colon carcinogenesis as
outlined in Figure 2B. Significantly, removal of one YAP1 allele
was sufficient to reduce tumor formation in N1/2 cDKO mice
from 15 to 5 nodules on average (compare Figures 2D and
4F). Therefore, NDR is functionally required to restrict the
oncogenic potential of YAP1 in the intestinal epithelium.
NDR Functions as a YAP1 Kinase Phosphorylating YAP1
on Serine 127
Given the intriguing inverse correlation between NDR loss,
decreased YAP1 phosphorylation, and increased YAP1 activ-
ity in the intestine (Figure 4), we investigated whether NDR
impacts directly on YAP1 regulation. To address whether
and where NDR phosphorylates YAP1 directly, we performed
in vitro kinase assays with recombinant human YAP1 andNDR-PIF, a constitutively active form of NDR [36]. Indeed,
active, but not kinase-dead, NDR-PIF phosphorylated YAP1
as determined by autoradiography (Figure 5A, middle panel).
Subsequent western blotting revealed that NDR phosphory-
lates YAP1 on S127 (Figure 5A, top panel), identifying for the
first time a YAP1-S127 kinase distinct from LATS1/2. Next,
we performed mass spectrometry to determine additional
sites on YAP1 targeted by NDR, identifying three additional
serines, namely S61, S109, and S164, to also be phosphory-
lated by NDR in vitro (Table S2). Significantly, all four sites—
S61/S109/S127/S164—are also phosphorylated by LATS [4,
32], suggesting that LATS and NDR kinases can function as
YAP1 kinases. Collectively, our kinase assays clearly establish
NDR kinases as novel bona fide upstream kinases of YAP1
in vitro.
To investigate whether NDR kinases function as YAP1 ki-
nases in mammalian cells, we overexpressed NDR in the colon
Figure 5. NDR Kinases Phosphorylate hYAP1 on Ser127
(A) Constitutively active NDR1 (glutathione S-transferase [GST]-NDR1-PIF) phosphorylates GST-YAP1 on serine 127. Kinase assays were carried out with
the indicated proteins in the presence of radiolabeled ATP (32P). Kinase-dead (KD) NDR1 serves as negative control. Top: western blot with phospho-S127
YAP1 antibody; middle: autoradiography; bottom: Coomassie (loading control). See also Table S2.
(B) Endogenous protein levels of phospho-S127 YAP1, phospho-S381 YAP1, and total YAP1 in SW480 cells transiently overexpressing the indicated
hemagglutinin (HA)-tagged NDR constructs. Phospho-S127 YAP1 levels (normalized to total YAP1 and vector control) are shown.
(C) Endogenous protein levels of phospho-127 YAP1, phospho-381 YAP1, and total YAP1 in stable SW480 cell pools that overexpress untaggedwild-type or
kinase-dead NDR2 in a tetracycline-inducible manner. LATS1 levels remained stable. Phospho-S127 YAP1 levels (normalized to total YAP1 and vector con-
trol) are shown.
301cancer cell line SW480 and assessed S127 phosphorylation
(Figure 5B). In line with our hypothesis that NDR regulates
YAP1 by phosphorylation, we found that wild-type—but not
inactive—NDR increased the ratio of S127 phosphorylation
significantly (Figure 5B). Contrarily, S381 phosphorylation
was unaffected (Figure 5B). Inducible overexpression of NDR
in stably transfected SW480 cells (tet-on system) and transient
transfection experiments in HCT116 cells yielded comparable
results (Figure 5C; Figure S4B), excluding the possibility that
the observed effects are cell line specific. In summary, our
data demonstrate that NDR kinases phosphorylate YAP1
directly on serine 127 in vitro and in tissue-cultured cells.
Significantly, these findings fully support our initial observation
of decreased S127 phosphorylation in N1/2 cDKO animals
in vivo (Figure 4A).
NDR Regulates the Localization and Transcriptional
Activity of YAP1
Considering that phosphorylation of YAP1 at S127 can result
in the inactivation of YAP1 by cytoplasmic retention [4, 6]
and that NDR phosphorylates YAP1 at S127 (Figure 5), we
reasoned that NDR overexpression might reduce nuclear
YAP1 levels and consequently YAP1 activity as a trans-
criptional coactivator. To test this hypothesis, we quantified
endogenous YAP1 localization by immunofluorescence in
our tetracycline (tet)-inducible colon cancer cell lines
described above (Figure 5C). The ratio of nuclear versus cyto-
plasmic YAP1 was significantly reduced in cells overexpress-
ing wild-type NDR compared to controls that overexpressed
kinase-dead NDR (Figure 6A). Signals for total YAP1 levels
were also reduced upon overexpression of active NDR (Fig-
ure 6A). The same was observed in a transient overexpression
setting (Figure S4A). Because the exclusion of YAP1 from the
nucleus was dependent on NDR kinase activity (Figure 6A; Fig-
ure S4A), these results suggest that this regulatory event is
controlled by NDR-mediated YAP1 phosphorylation.
Nuclear YAP1 associates with TEAD transcription factors
(TFs) to drive target gene expression [1]. Therefore, we as-
sessed whether NDR-mediated YAP1 phosphorylation inter-
feres with endogenous YAP1 transcriptional activity. Making
use of a published TEAD luciferase reporter assay [37], we
found that overexpression of wild-type NDR led to a 7-folddrop in reporter activity (Figure 6B). Conversely, overexpres-
sion of kinase-dead NDR resulted in a 2.7-fold increase,
suggesting that catalytically inactive NDR acts in a domi-
nant-negative manner as already reported in another setting
[15]. Collectively, these data indicate that NDR can suppress
YAP1 activity in a kinase activity-dependent manner, resulting
in cytoplasmic retention of YAP1 when NDR kinase is
overexpressed.
Considering that YAP1 drives proliferation in colon cancer
[10, 38] and that NDR negatively regulates YAP1 levels and ac-
tivity, we asked next whether NDR negatively affects YAP1-
dependent proliferation of human colon cancer cells. In full
agreement with a previous report [10], knockdown of YAP1
in SW480 cells reduced proliferation (Figures S4C and S4D),
illustrating that proliferation of SW480 cells is YAP1 depen-
dent. Significantly, we observed a similar effect upon tet-
induced overexpression of wild-type NDR in SW480 cells
(Figure 6C). Overexpression of kinase-dead NDR had no effect
(Figure 6C), showing that proliferation was negatively affected
in a manner dependent on NDR kinase activity. Moreover,
overexpression of wild-type NDR significantly suppressed
colony formation in contrast to controls (Figure 6D). Overex-
pression of kinase-dead NDR had no suppressive effect (Fig-
ure 6D). Collectively, these findings demonstrate the negative
impact of NDR kinase activity on the proliferative capacity of
colon cancer cells. This observation parallels our findings
that NDR loss in vivo increases proliferation (Figure 1) and
sensitizes mice to adenocarcinoma nodule formation upon
exposure to AOM (Figure 2). Mechanistically, these findings
demonstrate that forced expression of active NDR results in
a redistribution of YAP1 protein to the cytoplasm and
decreased transcriptional activity of YAP1. Functionally, our
data indicate that active NDR restricts proliferation of colon
cancer cells.
Finally, we turned to clinical colon cancer samples to
address the relevance of our findings in human patients.
Initially, we detected an inverse correlation of NDR2 and
YAP1 protein expression in six out of ten adenocarcinoma
samples. More specifically, YAP1 expression was elevated
in the tumor and low in the adjacent normal crypts, whereas
the opposite was true for NDR2 (Figure 7A). To increase
the spectrum of our analysis, we assessed YAP1 and NDR2
Figure 6. NDR Regulates the Cellular Distribution and Transcriptional Activity of YAP1
(A) Left: cellular distribution of endogenous YAP1 in SW480 cells overexpressing wild-type or kinase-dead Ndr2 in a tet-inducible manner (top: immunoflu-
orescent [IF] staining for YAP1; bottom: merge of IF YAP1 and 40,6-diamidino-2-phenylindole [DAPI]). Right: quantification of the nuclear/cytoplasmic YAP1
ratio per cell (n = 50 per condition). Student’s t test: *p = 6 3 1026. Scale bars represent 10 mm.
(B) TEAD-luciferase reporter assay in SW480 cells transiently transfected with empty vector, WT, or KD Ndr2. Firefly luciferase activity was normalized to
Renilla signal (n = 3). Student’s t test: *p = 1 3 1027.
(C) Proliferation curves of SW480 cells expressing WT or KD Ndr2 in a tet-inducible manner.
(D) Colony formation assay with the same cell lines as in (C). Colony numbers were scored 10 days after seeding (n = 3). Student’s t test: *p = 9 3 1023.
See also Figure S4.
302protein levels in a tissue microarray with 325 independent hu-
man colon cancer samples. Examples of high and low NDR2
andYAP1 scores as determined by IHCare shown in Figure 7B.
Significantly, the majority of human tumors with increased
YAP1 levels expressed only low amounts of NDR2 whereas
NDR2 expression in YAP1-low tumors was variable (Figure 7C;
Table S3), in line with our observation that, inmice, YAP1 levels
in the intestinal epithelium are increased in the absence of NDR
(Figure 4). Collectively, this analysis of clinical samples indi-
cates that NDR2 kinase might also play a tumor-suppressive
role in the human intestine.
Discussion
In the present study, we identify mammalian NDR1/2 as novel
YAP1 kinases in vitro and in vivo. Recombinant NDR phos-
phorylates YAP1 on S127 and other reported LATS sites. In
tissue-cultured cells, NDR regulates YAP1 function and
phosphorylation in a kinase activity-dependent manner. Loss
of NDR in the murine intestinal epithelium results in decreased
YAP1 phosphorylation, increased total YAP1 levels, and,
consequently, elevated cotranscriptional activity of YAP1
in vivo. Most importantly, ablation of NDR in vivo deregulates
YAP1 levels and activity without obviously altering MST1/2-
LATS1/2 signaling, strongly suggesting that the observed
deregulation of YAP1 is a direct effect of the absence of NDR
kinases.
Mammalian NDR kinases are the closest homologs of LATS
kinases [12], the only established YAP1-S127 kinases so far.NDR and LATS kinases efficiently phosphorylate the same
synthetic substrate peptide [39, 40] and a peptide based on
the sequence surrounding S127 on YAP1 [32]. Moreover,
NDR and LATS kinases appear to be regulated in a similar
fashion [3]. MST1/2 kinases can function as upstream kinases
of LATS [41] and NDR [14, 17], and hMOB1 proteins act as co-
activators for both NDR [14, 17, 42–44] and LATS kinases [39,
45–47]. Similar regulatory parallels have been observed in flies,
namely that Hippo, the fly homolog of mammalian MST1/2,
functions upstream of both Lats and Trc, the fly counterparts
of NDR/LATS [48]. Likewise, the coactivator Mats/dMOB1,
the homolog of hMOB1, regulates Lats and Trc in flies [49,
50]. Therefore, given that NDR and LATS kinases share similar
regulatory mechanisms and substrate signatures [3], our dis-
covery of NDR as a novel S127 kinase fits perfectly into the
context of previously published data. Furthermore, our find-
ings, together with the published regulatory similarities, sug-
gest that MST1/2-MOB1 signaling might use diverse routes
to regulate YAP1 phosphorylation. Therefore, future studies
of NDR/Trc signaling downstream of MST/Hippo and MOB1/
Mats are warranted in yet-to-be-established animal models.
Mechanistically, NDR-mediated YAP1-S127 phosphoryla-
tion drives cytoplasmic sequestration of YAP1 and suppresses
YAP1-driven reporter activity (Figure 6). These observations
recapitulate the effects reported for LATS on YAP1 in tissue-
cultured cells [4]. Functionally and in full support of our finding
that NDR negatively regulates YAP1 activity, NDR impairs
proliferation and colony formation of YAP1-dependent colon
cancer cells (Figure 6). Conversely, combined loss of murine
Figure 7. NDR2 and YAP1 Levels Are Inversely Correlated in Human Colon Cancer Samples
(A) YAP1 (blue) and NDR2 (brown) IHC staining in human colon adenocarcinoma and adjacent normal colon crypts. Scale bars represent 50 mm.
(B) Representative images of YAP1 and NDR2 IHC staining score in human colon cancer tissue microarrays (n = 400).
(C) NDR2 expression in tissue microarray samples with high versus low YAP1 levels. Absolute sample numbers are provided in the Supplemental Experi-
mental Procedures.
See also Table S3.
303NDR1/2 in the intestinal epithelium results in reduced YAP1
phosphorylation, whereas total YAP1 protein levels are
increased (Figure 4). On a functional level in the intestine,
YAP1 transcriptional coactivator activity is increased (Figure 4)
and the proliferative zone of the epithelium is extended (Fig-
ure 1). Therefore, to our knowledge, the Ndr KO mice
described in this study are the first animal model providing
comprehensive in vivo evidence of a direct YAP1-S127 kinase.
Follow-up studies are now needed to examine whether NDRs
also function as S127 kinases in other organs such as the liver,
whose tissue homeostasis is tightly regulated by YAP1 phos-
phorylation [9].
Although numerous studies have investigated S127 phos-
phorylation and its impact on YAP1 regulation (reviewed in
[1, 30]), additional sites on YAP1 are phosphorylated by
LATS, namely S61, S109, S164, and S381 [4, 32]. Phosphoryla-
tion at S381 primes YAP1 for proteasome-mediated degrada-
tion [31], whereas the function of the other phospho sites has
remained enigmatic [3]. We found that NDR targets S61, S109,
and S164 (Table S2) but did not observe S381 phosphoryla-
tion. In this context, the levels of phospho-S382, the murine
equivalent of hYAP1 S381, are comparable in the intestinal
epithelium ofN1/2 cDKO and control mice (Figure 4), and over-
expression of active NDR does not increase S381 phosphory-
lation in tissue-cultured cells (Figure 5). Interestingly, total
YAP1 protein levels are still increased in the absence of NDR
(Figure 4) and decreased upon NDR overexpression (Figure 5),
suggesting that alternative mechanisms to S381 phosphoryla-
tion must exist to regulate YAP1 protein levels in vivo. Whether
these mechanisms are mediated by the other identified phos-
phorylation sites—S61, S109, or S164—or triggered by more
indirect effects remains to be addressed with regard to NDR
signaling.
Ablation of mammalian Hippo—Mst1/2—in the intestinal
epithelium results in hyperproliferation through YAP1 upregu-
lation [10]. However, the direct physiological S127 kinase in
this tissue was not defined experimentally [10]. Mice with spe-
cific LATS1/2 deletion in the intestinal epithelium have not
been reported thus far. Instead, we show that NDR1/2 loss in
the intestinal epithelium leads to increased proliferation and
the formation of hyperplastic foci (Figure 1). Therefore, we
are tempted to speculate that MST1/2 kinases restrict prolifer-
ation in the intestinal epithelium at least in part via NDR kinase
signaling. However, loss of NDR1/2 in the intestinal epithelium
results in a substantially weaker YAP1-dependent phenotypethan ablation of Mst1/2 [10] or Sav1, a scaffold protein of the
MST1/2 kinase complex [11]. This indicates that MST1/2 ki-
nases presumably regulate additional downstream targets
distinct from NDR that impact on YAP1 regulation in the intes-
tinal epithelium. Clearly more work is required to test whether
LATS or other yet-to-be-identified YAP1 kinases/regulators
play a role in controlling YAP1 in the intestinal epithelium.
Already-reported mouse models provide strong evidence
suggesting that loss of S127 phosphorylation mimicked by
the introduction of an S127A YAP1 mutant or loss of the
MST1/2 upstream kinases is sufficient to drive hyperprolifera-
tion, expansion of progenitor cell compartments, and tumori-
genesis in the intestinal epithelium [5, 10]. Although N1/2
cDKO animals do not develop spontaneous tumors, they are
exquisitely more sensitive to chemically induced colon carci-
nogenesis than wild-type controls (Figure 2). Significantly,
this hypersensitivity is reduced by concomitant removal of
one Yap1 allele (Figure 4E), indicating that loss of NDR drives
carcinogenesis through YAP1 in the intestinal epithelium.
Importantly, we observe that only combined loss of both
NDR1 and NDR2 gives rise to the full tumor phenotype (Fig-
ure 2) and hyperproliferation (Figure 1), supporting our earlier
speculations [16] that NDR2 can partially compensate for the
absence of NDR1 in Ndr1 KO mice. In further support of a
tumor-suppressive function of NDR2 in the intestinal epithe-
lium, we found that loss of NDR2 correlates with tumor onset
in wild-typemicewith chemically induced carcinogenesis (Fig-
ure 3). Of equal importance, the majority of patient samples on
a colon cancer tissue microarray displayed an inverse correla-
tion between high YAP1 and low NDR2 levels (Figure 7).
Collectively, these findings suggest that NDR2 may serve a
tumor-suppressive role in human colorectal cancer.
In summary, we establish mammalian NDR as bona fide ki-
nases phosphorylating YAP1 on the key regulatory site S127
in vitro and in vivo. NDR kinases function as tumor suppres-
sors in the intestinal epithelium by negatively regulating
YAP1. In general, our data strongly suggest that the contribu-
tion of NDR kinases to YAP1 regulation should be accounted
for in future YAP1-related studies and reconsidered in set-
tings where the nature of the direct S127 kinase has remained
elusive. Collectively, our findings provide significant new
insights for a broad range of research efforts aimed at decod-
ing and eventually manipulating YAP1-driven biology with
the aim of improving cancer treatment and regenerative
medicine.
304Experimental Procedures
Animal Experiments
All animal experiments were carried out in compliance with animal welfare
regulation and approved by the Swiss Cantonal Veterinary Office of Basel.
Colon Carcinogenesis Model
Adult mice (aged 10 weeks, body weightR20 g) of the indicated Ndr geno-
types were injected intraperitoneally with 7.4 mg/kg body weight AOM
(Sigma) on day 1. From day 14 to day 21, drinking water was supplemented
with 2% DSS (MP Biomedicals). On day 64, mice were sacrificed and tissue
samples were collected for analysis.
Human Colon Cancer Tissue Microarray
A tissue microarray (TMA) of unselected, nonconsecutive human colorectal
cancer (CRC) samples was described previously [51]. In brief, formalin-
fixed, paraffin-embedded tissue blocks of CRC resections were retrieved
from the archives of the Institute of Pathology, University Hospital Basel,
and the Institute of Clinical Pathology, Basel. A table with clinicopatholog-
ical features of each sample is available upon request. Failure of analysis
(<10% of all cases) was related to TMA technology, including missing sam-
ples or fractions containing only a few tumor cells. The NDR2 and YAP IHC
staining protocols were identical to those established for mouse samples
(see the Supplemental Experimental Procedures).
See the Supplemental Experimental Procedures for detailed descriptions
of kinase assays, tissue-culture experiments, plasmids, antibodies,
and IHC.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, four figures, and three tables and can be found with this article online
at http://dx.doi.org/10.1016/j.cub.2014.11.054.
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